Higher single dose of bortezomib plus thalidomide and dexamethasone is a promising therapy for newly diagnosed multiple myeloma

BACKGROUND: Bortezomib in combination with thalidomide and dexamethasone (VTD) has been widely used for newly diagnosed multiple myeloma (MM). The aim of this study was to evaluate the efficacy and safety of a new high-dose bortezomib plus thalidomide and dexamethasone as an induction and consolidat...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Peipei, Zhou, Rongfu, Xu, Jingyan, Ouyang, Jian, Shao, Xiaoyan, Chen, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797627/
https://www.ncbi.nlm.nih.gov/pubmed/35116959
http://dx.doi.org/10.21037/tcr.2019.09.22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797627/
https://www.ncbi.nlm.nih.gov/pubmed/35116959
http://dx.doi.org/10.21037/tcr.2019.09.22

Ejemplares similares